Medical Abortion at Gestational Age ≤ 24 weeks at Songklanagarind Hospital

Main Article Content

Wannaporn Sudsai
Chitkasaem Suwanrath
Thanapan Choobun


Objectives: To determine the success and complication rates of medical abortion at gestational age < 24 weeks, and to identify their associated factors.
Materials and Methods: A retrospective study was conducted from January 2006 to December 2017. Medical records of pregnant women at gestational age ≤ 24 weeks, who were admitted for medical abortion, were reviewed. Spontaneous abortion was excluded. Multivariate logistic regression analysis was used to identify factors associated with success and complications. A p value of < 0.05 was considered statistically significant.
Results: A total of 717 cases were reviewed. Two medical regimens were used, including misoprostol alone (84.7%) and mifepristone-misoprostol (MM) (15.3%). The overall success rates in the first and second trimester were 65.8% and 79.3%. The highest success rate was observed in women at gestational age of ≤ 9 weeks, with the MM regimen (92.0%). The overall complication rate was 5.3%, including hemorrhage requiring blood transfusion (4.7%) and infection (0.6%). The complication rates in the first and second trimester were 2.5% and 5.6%, respectively. One factor associated with success in the first trimester was the drug regimen (MM); while that in the second trimester was maternal age. Multivariate analysis showed that factors associated with complications in the second trimester were multigravida and having an underlying disease.
Conclusion: Medical abortion at gestational age ≤ 24 weeks had low complications. Multigravida and having an underlying disease were factors associated with complications in the second trimester.


Download data is not yet available.

Article Details

Original Article


Kulier R, Kapp N, Gülmezoglu AM, Hofmeyr GJ, Cheng L, Campana A. Medical methods for first trimester abortion. Cochrane Database Syst Rev 2011:CD002855.

Baiju N, Acharya G, D'Antonio F, Berg RC. Effectiveness, safety and acceptability of self-assessment of the outcome of first-trimester medical abortion: a systematic review and meta-analysis. BJOG 2019;126:1536-44.

Tang OS, Ho PC. Medical abortion in the second trimester. Best Pract Res Clin Obstet Gynaecol 2002;16:237-46.

Shah D, Rijal P, Thakur A, Rai R. Mifepristone and misoprostol vs misoprostol alone in second trimester termination of pregnancy. J Nepal Med Assoc 2018;56:856-60.

Abubeker FA, Lavelanet A, Rodriguez MI, Kim C. Medical termination for pregnancy in early first trimester (< 63 days) using combination of mifepristone and misoprostol or misoprostol alone: a systematic review. BMC Womens Health 2020;20:142.

Meena SR. Comparative study of mifepristone with vaginal misoprostol for first trimester termination of pregnancy at different gestational ages. J Obstet Gynaecol India 2016;66:426-30.

Raymond EG, Trussell J, Polis CB. Cost-effectiveness of increased access to emergency contraceptive pills: probably not. Contraception 2013;87:504-8.

Lerma K, Shaw KA. Update on second trimester medical abortion. Curr Opin Obstet Gynecol 2017;29:413-8.

Fiala C, Cameron S, Bombas T, Parachini M, Agostini A, Lertxundi R, et al. Outcome of first trimester medical termination of pregnancy: definitions and management. Eur J Contracept Reprod Health Care 2018;23:451-7.

Carlsson I, Breding K, Larsson PG. Complications related to induced abortion: a combined retrospective and longitudinal follow-up study. BMC Womens Health 2018;18:158-66.

Heikinheimo O, Suhonen S, Haukkamaa M. One- and 2-day mifepristone-misoprostol intervals are both effective in medical termination of second-trimester pregnancy. Reprod Biomed Online 2004;8:236-9.

Morris JL, Winikoff B, Dabash R., Weeks A, Faundes A, Gemzell-Danielsson K, et al. FIGO’s updated recommendations for misoprostol used alone in gynecology and obstetrics. Int J Gynaecol Obstet 2017;138:363-6.

Kapp N, Eckersberger E, Lavelanet A, Rodriguez MI. Medical abortion in the late first trimester: a systematic review. Contraception 2019;99:77-86.

Dahiya K, Ahuja K, Dhingra A, Duhan N, Nanda S. Efficacy and safety of mifepristone and buccal misoprostol versus buccal misoprostol alone for medical abortion. Arch Gynecol Obstet 2012;285:1055-8

Goldstone P, Walker C, Hawtin K. Efficacy and safety of mifepristone-buccal misoprostol for early medical abortion in an Australian clinical setting. Aust N Z J Obstet Gynaecol 2017;57:366-71.

Ireland LD, Gatter M, Chen AY. Medical compared with surgical abortion for effective pregnancy termination in the first trimester. Obstet Gynecol 2015;126:22-8.

Nissi R, Santala M, Immonen E, Talvensaari-Mattila A. Mifepristone and misoprostol is safe and effective method in the second-trimester pregnancy termination. Arch Gynecol Obstet 2016;294:1243-7.

Nigam A, Singh VK, Prakash A. Vaginal vs. oral misoprostol for mid-trimester abortion. Int J Gynaecol Obstet 2006;92:270-1.

Wong KS, Ngai CS, Wong AY, Tang LC, Ho PC. Vaginal misoprostol compared with vaginal gemeprost in termination of second trimester pregnancy. A randomized trial. Contraception 1998;58:207-10.

Wong KS, Ngai CS, Yeo EL, Tang LC, Ho PC. A comparison of two regimens of intravaginal misoprostol for termination of second trimester pregnancy: a randomized comparative trial. Hum Reprod 2000;15:709-12.

Pongsatha S, Tongsong T. Intravaginal misoprostol for pregnancy termination. Int J Gynaecol Obstet 2004;87:176-7.

Allen R, O'Brien BM. Uses of misoprostol in obstetrics and gynecology. Rev Obstet Gynecol 2009;2:159-68.

Haimov-Kochman R, Arbel R, Sciaky-Tamir Y, Brzezinski A, Laufer N, Yagel S. Risk factors for unsuccessful medical abortion with mifepristone and misoprostol. Acta Obstet Gynecol Scand 2007;86:462-6.

Bartley J, Tong S, Everington D, Baird DT. Parity is a major determinant of success rate in medical abortion: a retrospective analysis of 3161 consecutive cases of early medical abortion treated with reduced doses of mifepristone and vaginal gemeprost. Contraception 2000;62:297-303.